Author Affiliation: Department of Cardiology, Cleveland Clinic Florida, Weston.
Despite advances in its medical management, severe congestive heart
failure remains associated with substantial morbidity and mortality. Prognosis
has improved only slightly during the past decade among unselected community
patients with congestive heart failure.1 It
appears that the benefits documented in large randomized clinical trials have
not been fully realized. Two articles in this issue of THE JOURNAL describe
encouraging findings regarding 2 relatively novel therapeutic approaches for
congestive heart failure: β-blockers and cardiac resynchronization therapy.
Pinski SL. Continuing Progress in the Treatment of Severe Congestive Heart Failure. JAMA. 2003;289(6):754-756. doi:10.1001/jama.289.6.754